Embed Size (px)
Citation preview
1
DAN TURNER
LIST OF PUBLICATIONS
Doctoral Dissertation
"Development, evaluation and application of a pediatric ulcerative colitis activity index".
Supervisors: Prof AH Steinhart & Prof AM Griffiths. URI:
http://hdl.handle.net/1807/11268
Book chapters and other publications
1. Noble A, Turner D. Clinical outcomes in pediatric Inflammatory Bowel Disease. In:
Pediatric Inflammatory Bowel Disease, Mamula P, Markowitz JE, Baldassano RN,
Eds, 2008. 744 p., ISBN: 978-0-387-73480-4
2. Bousvaros A, Turner D, Vitito L. Monitoring disease activity in Pediatric IBD
patients. A continuing medical education monograph series. NASPGHAN and
CDHNF 2009
3. Turner D. A commentary on- Utility of three endoscopic IBD activity scores
highlighted in two studies. GI & Hepatology News 2013
4. Turner D, Day AS. Inflammatory Bowel Diseases- treatment algorithms. In:
Practical Algorithms in Pediatric Gastroenterology, Shaoul R Eds 2014. Karger,
Switzerland
Peer review manuscripts
1. Turner D, Porat N, Cohen D, Yavzori M, Frazer D, Peled N, Ohana O, Dagan R.
Antibiotic resistance pattern of enterotoxigenic Escherichia coli isolated from
infants and young adults in Israel. Eur J Clin Microbiol Infect Dis 1998;17:666-
669.
2. Turner D, Dagan R. The sensitivity of common bacteria to antibiotics in children
in the south of Israel. Harefua 2001;140(10):923-929.
3. Turner D, Leibovitz E, Aran A, Piglansky L, Raiz S, Leiberman A, Dagan R.
Acute otitis media in infants younger than two months of age: microbiology,
clinical presentation and therapeutic approach. Pediat Infect Dis J 2002;21:669-674.
4. Turner D, Einhorn M. Group A Streptoccocal osteomyelitis-severe presentation
and course. Acta Paediatr 2003;92(1):125-127.
5. Weinstein M, Turner D, Avitzur Y. Erythema nodosum as a presentation of
inflammatory bowel disease. Can Med Assoc J 2005;173(2):145-146.
6. Turner D, Martin S, Ngan BY, Grant D, Sherman PM. Anastomotic ulceration
following small bowel transplantation. Am J Transplant 2006;6:236–240.
7. Schmid T, Turner D, Oberbaum M, Finkelstein Y, Bass R, Kleid D. Respiratory
failure in a neonate after folk treatment with broom bush (Retama Raetam) extract.
Pediatr Emerg Care 2006;22(2):124-126.
2
8. Turner D, Lurie Y, Finkelstein Y, Schmid T, Gopher A, Kleid D, Bentur Y.
Pediatric cinnarizine overdose and toxicokinetics. Pediatrics 2006;117:e1067-
e1069.
9. Turner D, Hammerman C, Bernard R, Schlesinger Y, Goia C, Schimmel MS.
Procalcitonin in preterm infants during the first few days of life: introducing an age
related nomogram. Arch Dis Child Fetal Neonatol Ed 2006;91:F283-F286.
10. Turner D, Schreiber R, Grant D, Hebert D, Sherman PM. Hemolytic uremic
syndrome following pediatric liver transplantation. J Pediatr Gastroenterol Nutr
2006;43:109-112.
11. Turner D, Hammerman C, Bernard R, Schlesinger Y, Schimmel MS. The role of
procalcitonin as a predictor of nosocomial sepsis in preterm infants. Acta
Paediatrica 2006;95:1571-1576.
12. Muise AM, Turner D, Wine E, Kim P, Marcon M, Ling CS. Biliary atresia
associated with choledochal cyst: implication for classification. Clin Gastroenterol
Hepatol 2006;4:1411-1414.
13. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Outcome of intravenous
corticosteroid therapy in ulcerative colitis: a systematic review of the literature and
meta-regression. Clin Gastroenterol Hepatol 2007;5:103-110.
14. Turner D, Zlotkin SH, Shah PS, Griffiths AM. Omega 3 fatty acids (fish oil) for
maintenance of remission in Crohn's disease. Cochrane Database of Syst Rev 2007;
Issue 2:CD006320.
15. Turner D, Otley AR, Mack D, de Bruijne J, Uusoue K, Walters T, Zachos M,
Mamula P, Hyams J, Beaton DE, Steinhart AH, Griffiths AM. Development and
complete evaluation of a Pediatric Ulcerative Colitis Activity Index (PUCAI): A
prospective multicenter study. Gastroenterology 2007;133:423-432.
16. Turner D, Steinhart AH, Griffiths AM. Omega 3 fatty acids (fish oil) for
maintenance of remission in ulcerative colitis. Cochrane Database of Syst Rev
2007; Issue 3: CD006443
17. Turner D, Grossman AB, Rosh, J, Kugathasan S, Gilman AR, Baldassano R,
Griffiths AM. Methotrexate following unsuccessful thiopurine therapy in pediatric
Crohn’s disease. Am J Gastroenterol 2007;102:2804–2812.
18. Turner D, Hammerman C, Bernard R, Schlesinger Y, Wine E, Muise A, Schimmel
MS. Low levels of procalcitonin during episodes of necrotizing enterocolitis. Dig
Dis Sci 2007;52:2972-2976.
19. Muise AM, Walters TD, Wine E, Griffiths AM, Turner D, Duerr RH, Regueiro
MD, Ngan BY, Xu W, Sherman PM, Silverberg MS, Rotin D. Protein Tyrosine
Phosphatase Sigma is associated with ulcerative colitis. Curr Biol 2007;17:1212-
1218.
20. Turner D, Walsh CM, Benchimol EI, Mann EH, Thomas KE, Chow C, McLernon
RA, Walters TD, Steinhart AH, Griffiths AM. Severe paediatric ulcerative colitis:
incidence, outcomes, and optimal timing for second line therapy. Gut 2008; 57:331-
338.
21. Turner J, Turner D, Riopelle RJ, Bassett-Spiers K, Kagan C. ONF trainee awards
contribute to capacity building in neurotrauma. Can J Neuro Sc 2008; 35:85-90.
3
22. Benchimol EI, Turner D, Mann EH, Thomas KE, McLernon RA, Griffiths AM.
Toxic megacolon in children with inflammatory bowel disease: clinical and
radiographic characteristics. Am J Gastroenterol 2008; 103:1524-1531.
23. Sivagnanam M, Mueller JL, Lee H, Chen Z, Nelson SF, Turner D, Nagn BY,
Zlotkin SH, Pencharz PB, Libiger O, Schork NJ, Lavine JE, Taylor S, Newbury
RO, Kolodner RD, Hoffman HM. Rapid identification of EpCAM as the gene for
congenital tufting enteropathy using only two individuals. Gastroenterology 2008;
135(2):429-437.
24. Turner D, Zlotkin SH, Shah PS, Griffiths AM. Omega 3 fatty acids (fish oil) for
maintenance of remission in Crohn's disease (update). Cochrane Database of Syst
Rev 2009; Issue 1:CD006320.
25. Turner D, Griffiths AM, Steinhart AH, Otley AR, Beaton DE. Mathematical
weighting of a clinimetric index (Pediatric Ulcerative Colitis Activity Index) was
superior to the judgmental approach. J Clin Epidemiol 2009;62(7):738-744.
26. Turner D, Schünemann HJ, Griffith LE, Beaton DE, Griffiths AM, Critch JN,
Guyatt GH. Using the entire cohort in the receiver operating characteristic analysis
maximizes precision of the minimal important difference. J Clin Epidemiol
2009;62(4):374-379.
27. Turner D, Hyams J, Markowitz J, Lerer T, Mack DR, Evans J, Pfefferkorn M,
Rosh J, Kay M, Crandall W, Keljo D, Otley AR, Kugathasan S, Carvalho R, Oliva-
Hemker M, Langton C, Mamula P, Bousvaros A, LeLeiko N, Griffiths AM.
Appraisal of the Pediatric Ulcerative Colitis Activity Index (PUCAI). Inflamm
Bowel Dis 2009; 15(8):1218-23.
28. Turner D. Severe acute ulcerative colitis: the pediatric perspective. Dig Dis
2009;27:322–326.
29. Turner D, Griffiths AM. Esophageal, gastric and duodenal manifestations of IBD,
and the role of upper endoscopy in IBD diagnosis. Curr Gastroenterol Rep
2009;11:234-237 (invited review).
30. Turner D, Seow CH, Greenberg GR, Griffiths AM, Silverberg MS, Steinhart AH.
A systematic prospective comparison of noninvasive disease activity indices in
ulcerative colitis. Clin Gastroenterol Hepatol 2009;7(10):1081-8.
31. Turner D, Benchimol EI, Dunn H, Griffiths AM, Frost K, Scaini V, Avolio J, Ling
SC. Pico-Salax versus Poly-Ethylene Glycol for bowel cleanout before
colonoscopy in children-a randomized controlled trial. Endoscopy 2009; 41:1038-
1045.
32. Gonska T, Ip W, Turner D, Han WS, Rose J, Durie P, Quinton P. Sweat gland
bioelectrics differ in cystic fibrosis: a new concept for potential diagnosis and
assessment of CFTR function in cystic fibrosis. Thorax 2009; 64(11):932-938.
33. Turner D, Beaton DE, Schunemann HJ, Griffiths AM, Kritch J, Griffith LE,
Guyatt GH. The minimal detectable change cannot reliably replace the minimal
important difference. J Clin Epidemiol 2010; 63(1):28-36.
34. Gana JC, Turner D, Roberts EA, Ling SC. Derivation of a clinical prediction rule
for the non-invasive diagnosis of varices in children. J Pediatr Gastroenterol Nutr
2010; 50(2):188-193.
35. Turner D, Kolho KL, Mack DR, Raivio T, Leleiko N, Crandall W, Markowitz J,
Silverberg M, Jänne OA, Stempak J, Hyams J, Griffiths AM. Glucocorticoid-
4
bioactivity does not predict response to steroid therapy in severe pediatric
ulcerative colitis. Inflamm Bowel Dis 2010;16(3):469-473.
36. Turner D, Griffiths AM, Mack D, Otley AR, Seow CH, Steinhart AH, Silverberg
MS, Hyams J, Guyatt GH. Assessing disease activity in ulcerative colitis: patients
or their physicians? Inflamm Bowel Dis 2010; 16(4):651-656.
37. Turner D, Ashkenazi S, Mimouni F, Shamir R. Recommendations for the
diagnosis and management of pediatric acute gastroenteritis in Israel. Harefuah
2010; 149(1): 53-58.
38. Turner D, Guyatt G. Reflections on the minimal important difference: research is
the ultimate goal, not the anchor. J Clin Epidemiol 2010;63:806 (Letter).
39. Turner D, Griffiths AM, Walters TD, Seah T, Markowitz J, Pfefferkorn M, Keljo
D, Otley A, Leleiko NS, Mack D, Hyams J, Levine A. Appraisal of the pediatric
Crohn's disease activity index on four prospectively collected datasets:
recommended cutoff values and clinimetric properties. Am J Gastroenterol
2010;105(9):2085-2092.
40. Turner D, Mack D, Leleiko N, Walters TD, Uusoue K, Leach ST, Day AS,
Crandall W, Silverberg MS, Markowitz J, Otley AR, Keljo D, Mamula P,
Kugathasan S, Hyams J, Griffiths AM. Severe pediatric ulcerative colitis: a
prospective multicenter study of outcomes and predictors of response.
Gastroenterology 2010;138(7):2282-2291.
41. Hudara S, Mimouni F, Rachman Y, Dayan B, Silbermintz A, Turner D.
Retrospective cohort study of a new infant formula during the first six months of
life: reflections about growth curves, human milk and formula feeding. IMAJ 2010;
12:676-680.
42. Turner D, Leach ST, Mack D, Uusoue K, McLernon R, Hyams J, Leleiko N,
Walters TD, Crandall W, Markowitz J, Otley AR, Griffiths AM, Day AS. Faecal
calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative
colitis: a prospective multicentre comparison of predicting outcomes and
monitoring response. Gut 2010;59(9):1207-1212.
43. Turner D, Levine A, Weiss B, Hirsh A, Shamir R, Shaoul R. Evidence-based
recommendations for bowel cleansing before colonoscopy in children: a report
from a national working group, the Israeli Society of Pediatric Gastroenterology
and Nutrition (ISPGAN). Endoscopy 2010; 42:1063-1070.
44. Kabakchiev B*, Turner D* (first co-author), Hyams J, Mack D, Leleiko N,
Crandall W, Markowitz J, Otley A, Xu W, Hu P, Griffiths AM, Silverberg M. Gene
expression changes associated with resistance to intravenous corticosteroid therapy
in children with severe ulcerative colitis. PLoS ONE 2010; 5(9).
45. Russell RK, Turner D. Management of severe pediatric ulcerative colitis. Inflamm
Bowel Dis Monit 2011;11(4):139–44.
46. Turner D, Shah PS, Steinhart AH, Zlotkin S, Griffiths AM. Maintenance of
remission in Inflammatory Bowel Disease using omega-3 fatty acids (fish oil): A
systematic review and meta-analyses. Inflamm Bowel Dis 2011; 17(1):336-45
(revised from earlier work).
47. Turner D, Griffiths AM. Acute Severe Ulcerative Colitis in Children: A
Systematic Review. Inflamm Bowel Dis; 2011 17(1):440-9 (invited manuscript).
5
48. Turner D, Travis SPL, Griffiths AM, Ruemmele FM, Levine A, Benchimol EI,
Dubinsky M, Alex G, Baldassano RN, Langer JC, Shamberger R, Hyams JS,
Cucchiara S, Bousvaros A, Escher JC, Markowitz J, Wilson DC, Assche G, Russell
RK. Consensus for managing acute severe ulcerative colitis in children: a
systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD
working group of ESPGHAN. Am J Gastroenterol 2011; 106(4):574-88.
49. Levine A, Bachar L, Tsangen Z, Mizrachi A, Levy A, Dalal I, Kornfeld L, Levy Y,
Zadik Z, Turner D, Boaz M. Screening criteria for diagnosis of infantile feeding
disorders as a cause of poor feeding or food refusal. J Pediatr Gastroenterol Nutr
2011; 52(5):563-568.
50. Sylvester FA* , Turner D* (First co-author), Draghi A, Uuosoe K, McLernon R,
Kaproske K, Mack DR, Crandall WV, Hyams JS, LeLeiko NS, Griffiths AM. Fecal
osteoprotegerin may guide the introduction of second line therapy in hospitalized
children with ulcerative colitis. Inflamm Bowel Dis 2011; 17(8):1726-30.
51. Levine A, Turner D. Combined azithromycin and metronidazole therapy is
effective for inducing remission in pediatric Crohn's disease. J Crohns Colitis
2011;5(3):222-6.
52. Levine A*, Griffiths AM*, Markowitz J*, Wilson DC*, Turner D* (all authors
contributed equally), Russell RK*, Fell J*, Ruemmele FM*, Walters TD*,
Sherlock M*, Dubinsky M*, Hyams JS*. Pediatric modification of the Montreal
classification for inflammatory bowel disease: The Paris classification. Inflamm
Bowel Dis 2011;17(6):1314-21.
53. Muise AM, Walters T, Xu W, Shen-Tu G, Guo CH, Lam GY, Bennitz J, Van
Limbergen J, Fattouh R, Renbaum P, Kasirer Y, Ngan BY, Turner D, Denson LA,
Sherman PM, Duerr RH, Cho J, Satsangi J, Wilson DC, Paterson AD, Griffiths
AM, Glogauer M, Silverberg MS, Brumell JH. Single nucleotide polymorphisms
that increase expression of the guanosine triphosphatase RAC1 are associated with
ulcerative colitis. Gastroenterology 2011;141(2):633-641.
54. Turner D, Mack DR, Hyams J, LeLeiko N, Otley A, Markowitz J, Kasirer Y,
Muise A, Seow CH, Silverberg MS, Crandall W, Griffiths AM. C-reactive protein
(CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in
pediatric ulcerative colitis. J Crohn Colitis 2011;5(5):423-429.
55. Turner D, Griffiths AM, Walters TD, Seah T, Markowitz J, Pfefferkorn M, Keljo
D, Waxman J, Otley A, Leleiko NS, Mack D, Hyams J, Levine A. Mathematical
weighting of the pediatric Crohn's disease activity index (PCDAI) and comparison
with its other short versions. Inflamm Bowel Dis 2012;18(1):55-62.
56. Turner D, Griffiths AM. CRP, ESR and pediatric ulcerative colitis: authors' reply.
J Crohn Colitis 2012;6(2):260 (Letter to the editor)
57. Lev-Tzion R, Turner D. Is pediatric IBD treatment different than in adults?
Minerva Gastroenterol Dietol 2012;58(2):137-150.
58. Dayan B, Turner D. Pediatric Radiation Doses and IBD. Inflamm Bowel Dis
2011;17(12):2594-2595. Invited commentary
59. Shaoul R, Sladek M, Turner D, Paerregaard A, Veres G, Veereman-Wauters G,
Escher J, Amil Dias J, Lionetti P, Staiano A, Kolho KJ, De Ridder L, Nuti F,
Cucchiara S, Shevah O, Levine A. Limitations of fecal calprotectin at diagnosis in
untreated pediatric Crohn’s disease. Inflamm Bowel Dis 2012;18(8):1493-1497.
6
60. Judd TA, Day AS, Lemberg DA, Turner D, Leach ST. An update of faecal
markers of inflammation in inflammatory bowel disease. J Gastroenterol Hepatol
2011;26:(10):1493-1499.
61. Michail S, Durbin M, Turner D, Griffiths AM, Mack D, Hyams J, Leleiko N,
Kenche H, Stolfi A, Wine E. Alterations in the gut microbiome of children with
severe ulcerative colitis. Inflamm Bowel 2012;18(10):1799-1808.
62. Turner D. Collaboration and networking- the name of the game in Pediatric IBD
(Editorial). J Pediatr Gastroenterol Nutr 2012;55(2):122.
63. Kolho KL, Turner D, Veereman-Wauters G, Sladek M, de Ridder L, Shaoul R,
Paerregaard A, Amil Dias J, Koletzko S, Nuti F, Bujanover Y, Staiano A,
Bochenek K, Finnby L, Levine A, Veres G. Rapid test for fecal calprotectin levels
in children with Crohn´s disease. J Pediatr Gastroenterol Nutr
2012;55(4):436-439.
64. Moran CJ, Walters TD, Guo CH, Kugathasan S, Klein C, Turner D, Wolters VM,
Bandsma RH, Mouzaki M, Langer JC, Cutz E, Benseler SM, Roifman C,
Silverberg MS, Griffiths AM, Snapper SB, Muise AM. IL-10R polymorphisms are
associated with very early-onset ulcerative colitis. Inflamm Bowel Dis
2013;19(1):115-123.
65. Turner D, Levine A, Escher JC, Griffiths AM, Russell RK, Dignass A, Dias JA,
Bronsky J, Braegger CP, Cucchiara S, de Ridder L, Fagerberg UL, Hussey S,
Hugot JP, Kolacek S, Kolho KL, Lionetti P, Pærregaard A, Potapov A, Rintala R,
Serban DE, Staiano A, Sweeny B, Veerman G, Veres G, Wilson DC, Ruemmele
FM. Management of Pediatric Ulcerative Colitis: A Joint ECCO and ESPGHAN
Evidence-Based Consensus Guidelines. J Pediatr Gastroenterol Nutr
2012;55(3):340-361.
66. Levine A, de Bie CI, Turner D, Cucchiara S, Sladek M, Murphy MS, Escher JC;
and the EUROKIDS Porto IBD Working Group of ESPGHAN. Atypical disease
phenotypes in pediatric ulcerative colitis: 5-year analyses of the EUROKIDS
Registry. Inflamm Bowel Dis 2013;19(2):370-377.
67. Dayan B, Turner D. The role of surgery in severe ulcerative colitis in the era of
medical rescue therapy. World J Gastroenterol 2012;18(29):3833-3838.
68. Turner D, Lev-Tzion R. Understanding infliximab in Crohn’s disease: the long-
term outcomes. Dig Dis Sci 2013; 58(3):604-607.
69. Gana JC, Turner D, Mieli-Vergani G, Davenport M, Miloh T, Avitzur Y, Yap J,
Morinville V, Brill H, Ling SC. Non-invasive diagnosis of esophageal varices in
children: a prospective multicentre validation study. Gastroenterology 2011;
141(6):2009-16.
70. Kasirer Y, Turner D. Management issues in adolescents with Crohn’s disease-
current practice. World J Gastroenterol 2013; In press.
71. Koslowsky B, Turner D. The Role of Infliximab in Pediatric Ulcerative Colitis. Int
J Clin Rev 2012; 04:02 doi: 10.5275.
72. Sutton GA, Dahan R, Turner D, Paltiel O. Behaviour-based Pain Scale for Horses
with Acute Colic –scale construction. Vet J 2013; 196 (3):394-401.
73. Turner D, Wolters VM, Russell RK, Shakhnovich V, Muise AM, Ledder O, Ngan
B, Friesen C. Anti-TNF, infliximab and adalimumab, can be effective in
7
eosinophilic bowel disease: a report of eight pediatric cases. J Pediatr Gastroenterol
Nutr 2013; 56(5):492-7.
74. Wine E, Mack DR, Hyams J, Otley AR, Markowitz J, Crandall WV, Leleiko N,
Muise AM, Griffiths AM, Turner D. Interleukin-6 is associated with steroid
resistance and reflects disease activity in severe pediatric ulcerative colitis. J Crohn
Colitis 2013; 7(11):916-22.
75. Kolho KL, Turner D. Fecal calprotectin and clinical disease activity in pediatric
ulcerative colitis. ISRN Gastroenterology 2013; 2013(179024).
76. Kasirer Y, Turner D, Lerman L, Schechter A, Waxman J, Dayan B, Bergwerk A,
Rachman Y, Frier Z, Silbermintz A. Scalloping is a reliable endoscopic marker for
celiac disease. Digestive Endoscopy 2014; 26(2):232-5.
77. Sutton GA, Paltiel O, Soffer M, Turner D. Validation of two behaviour-based pain
scales for horses with acute colic. Vet J 2013; 197(3):646-50.
78. Turner D, Griffiths AM, Veerman G, Johanns J, Damaraju L, Blank M, Hyams J.
Endoscopic and clinical predictors of 1-year outcome in children with ulcerative
colitis treated with infliximab: results from the T72 trial. Clin Gastroenterol
Hepatol 2013; 11(11):1460-5.
79. Turner D, Friesen C. Response to letter to the editor on eosinophilic enterocolitis.
J Pediatr Gastroenterol Nutr 2013; 57(4):e25-e26.
80. Levine A*, Turner D* (contributed equally), Pfeffer Gik T, Amil Dias J, Veres
G, Shaoul R, Staiano A, Escher JC, Kolho KL, Paerregaard A, Martin de Carpi J,
Veereman Wauters G, Koletzko S, Shevah O, Finnby L, Sladek M *. Comparison
of Outcomes for Induction of Remission by Exclusive Enteral Nutritional and
Medical Therapy in New Onset Pediatric Crohn's Disease: Evaluation of the Porto
IBD Group "Growth Relapse and Outcomes With Therapy" (GROWTH CD)
Cohort Study. Inflamm Bowel Dis 2013; 20(2):278-85.
81. Hashkes PJ, Becker ML, Cabral DA, Laxer RM, Paller A, Rabinovich CE, Turner
D, Zulian F. Methotrexate: New Uses for an Old Drug. J Pediatr 2014; 164(2):231-
6.
82. Ruemmele FM, Turner D. Differences in the management of pediatric and adult
onset UC- lessons from the ECCO-ESPGHAN-consensus-guidelines for the
management of pediatric UC. J Crohn Colitis 2014; 8(1):1-4.
83. de Ridder L, Turner D, Wilson D, Koletzko S, de-Carpi JM, Fagerberg UL, Spray
C, Sladek M, Shaoul R, Roma-Giannikou E, Bronsky J, Serban DE, Cucchiara S,
Veres G, Ruemmele FM, Hojsak I, Kolho KL, Davies I, Aloi M, Lionetti P,
Veereman G, Braegger C, Trindade E, Wewer V, Hauer A, Levine A. Malignancy
and mortality in pediatric patients with inflammatory bowel disease: a multinational
study from the Porto Pediatric IBD group. Inflamm Bowel Dis 2014; 20 (2):291-
300.
84. Kasirer Y, Mevorach R, Renbaum P, Algur N, Soiferman D, Beeri R, Rachman Y,
Segel R, Turner D. Thiopurine s-methyltransferase (TPMT) activity is better
determined by biochemical assay vs. genotyping in the Jewish population. Dig Dis
Sci 2014; 59(6):1207-12.
85. Turner D. Relapsing and refractory ulcerative colitis in children. Dig Dis 2014;
32(4):419-26.
8
86. Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, de Ridder L, Kolho KL,
Veres G, Russell RK, Paerregaard A, Burderus S, Greer MC, Dias JA, Veereman-
Wauters G, Lionetti P, Sladek M, de Carpi JM, Staiano A, Ruemmele FM, Wilson
DC. The ESPGHAN Revised Porto Criteria for the Diagnosis of Inflammatory
Bowel Disease in Children and Adolescents. J Pediatr Gastroenterol Nutr 2014;
58(6):795-806
87. Ruemmele FM, Hyams JS, Otley A, Griffiths AM, Kolho KL, Amil Dias J, Levine
A, Escher JC, Taminiau J, Veres G, Colombel JF, Vermeire S, Wilson DC, Turner
D. Outcome measures for clinical trials in paediatric inflammatory bowel disease:
an evidence-based, expert-driven practical statement paper of the paediatric ECCO
committee. Gut 2014; 12(0):1-9.
88. Lev-Tzion R, Griffiths AM, Ledder O, Turner D. Omega 3 fatty acids (fish oil) for
maintenance of remission in Crohn's disease. Cochrane Database of Syst Rev 2014;
Issue 1: CD00632.
89. Turner D, Levine A, Kolho KL, Shaoul R, Ledder O. Combination of oral
antibiotics may be effective in severe pediatric ulcerative colitis: a preliminary
report. J Crohn Colitis 2014; In press
90. Schechter A, Griffiths C, Gana JC, Shaoul R, Shamir R, Shteyer E, Bdolah-Abram
T, Ledder O, Turner D. Early endoscopic, laboratory and clinical predictors of
poor disease course in pediatric ulcerative colitis. Gut 2014; In press.
91. Martinelli M, Strisciuglio C, Veres G, Paerregard A, Mocic A, Aloi M, Levine A,
Martin Carpi FJ, Turner D, Del Pezzo M, Staiano A, Miele Eon behalf of Porto
IBD Working Group of ESPGHAN. Clostridium difficile and pediatric
Inflammatory Bowel Disease: a prospective, comparative, multicenter, ESPGHAN
study. Inflamm Bowel Dis 2014; In press
92. Uhlig HH, Schwerd T, Koletzko S, Shah N, Kammermeier J, Elkadri A, Ouahed J,
Wilson DC, Travis SP, Turner D, Klein C, Snapper SB, Muise AM. The
diagnostic approach to monogenic very early onset inflammatory bowel disease.
Gastroenterology 2014; In press.
93. Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, Amil Dias J,
Barabino A, Braegger CP, Bronsky J, Buderus S, Martín-de-Carpi J, De Ridder L,
Fagerberg UL, Hugot JP, Kierkus J, Kolacek S, Koletzko S, Lionetti P, Miele E,
Navas López VM, Paerregaard A, Russell RK, Serban DE, Shaoul R, Van Rheenen
P, Veereman G, Weiss B, Wilson D, Dignass A, Eliakim A, Winter H, Turner D.
Consensus guidelines of ECCO/ESPGHAN on the medical management of
pediatric Crohn's disease. J Crohns Colitis. 2014. In press
94. Cozijnsen MA, Escher JC, Griffiths AM, Turner D, de Ridder L. The benefits and
risks of combining anti-TNF with immunomodulator therapy in pediatric
inflammatory bowel disease. Inflamm Bowel Dis 2014; In press
95. Topf C, Turner D. How effective is the use of long term anti-TNF for pediatric
IBD? Clues from real life surveillance cohorts. Arch Dis Child 2014; In press
96. Turner D, Doveh E, Cohen A, Wilson ML, Grossman AB, Rosh J, Lu YL,
Bousvaros A, Deslandres C, Noble A, Baldassano R, Levine A, Lerner A, Wilson
DC, Griffiths AM. Efficacy of oral methotrexate in pediatric Crohn's disease: a
multicentre propensity score study. Gut 2014; In press
9
97. Colli A, Gana JC, Turner D, Yap J, Adams-Webber T, Ling SC, Casazza G.
Capsule endoscopy for the diagnosis of oesophageal varices in people with chronic
liver disease or portal vein thrombosis. Cochrane Database of Syst Rev 2014; In
press.
98. Church PC, Turner D, Feldman BM, Walters TD, Greer ML, Amitai MM,
Griffiths AM. Systematic review and meta-analysis: Magnetic resonance
enterography signs for the detection of inflammation and intestinal damage in
Crohn’s disease. Aliment Pharmacol Ther 2014; In press.
99. Halevy J, Turner D. Promoting research in a medical center- the management
narrative. Harefuah 2014; In press
100. Benharush D, Cohen MJ, Turner D. Short chain fatty acids (butyrate) for induction
of remission in ulcerative colitis. Cochrane Database of Syst Rev 2014; In press.
101. Winter DA, Karolewska-Bochenek K, Lazowska-Przeorek I, Lionetti P, Mearin
ML, Chong SK, Roma-Giannikou E, Maly J, Kolho KL, Shaoul R, Damen GM, de
Meij T, Hendriks D, George EK, Turner D, Escher JC. Pediatric IBD-Unclassified
is less common than previously reported; Results of an 8-year audit of the
EUROKIDS registry. Inflamm Bowel Dis 2015; In press
102. Lev-Tzion D, Renbaum P, Ledder O, Mevorach R, Algur N, Segel R, Karban K,
Koifman E, Efrati E, Muise A, Chowers Y, Turner D. RAC1 polymorphisms and
thiopurine efficacy in children with inflammatory bowel disease. J Pediatr
Gastroenterol Nutr 2015; In press
103. Heshin-Bekenstein M, Turner D, Shamir R, Bar-Meir M, Dagan R, Zevit N,
Silbermintz A. HBs Vaccine versus Pre-S Vaccine Immunization in Children with
Coeliac Disease (CD) Previously Vaccinated Against HBV - a Randomized
Controlled Trial. J Pediatr Gastroenterol Nutr 2015; In press
104. de Ridder L, Waterman M, Turner D, Bronsky J, Hauer AC, Dias JA,
Strisciuglio C, Ruemmele F, Levine A, Lionetti P. Use of biosimilars in
paediatric inflammatory bowel disease: position statements of the (Porto)
ESPGHAN IBD working group. J Pediatr Gastroenterol Nutrition 2015; In
press
105. Livshits A, Fisher D, Hadas I, Bdolah-Abram T, Mack D, Hyams J,
Crandall W, Griffiths AM, Turner D. Abdominal x-ray in pediatric acute
severe colitis and radiographic predictors of response to intravenous
steroids. J Pediatr Gastroenterol Nutrition 2015; In press
106. Birimberg-Schwartz L, Wilson DC, Kolho KL, Karolewska –Bochenek K, Afzal
NA, Spray C, Romano C, Lionetti P, Hauer AC, Martinez-Vinson C, Veres
G,.Escher JC, Turner D. pANCA and ASCA in children with IBD-unclassified,
Crohn’s Colitis and Ulcerative Colitis - a longitudinal report from the IBD Porto
group of ESPGHAN. Inflamm Bowel Dis 2016; In press
107. Turner D, Koletzko S, Griffiths AM, Hyams J, Dubinsky M, de Ridder L,
Escher JC, Lionetti P, Cucchiara S, Lentze MJ, Koletzko B, van Rheenen P,
Russell RK, Mack D, Veereman G, Vermeire S, Ruemmele F. Use of
placebo in pediatric inflammatory bowel diseases: A position paper from
ESPGHAN, ECCO, PIBDnet and the Canadian Children IBD Network. J
Pediatr Gastroenterol Nutrition 2015; In press
10
108. Turner D. Microscopic assessment in inflammatory bowel disease: the
more the merrier? J Pediatr Gastroenterol Nutrition 2015; In press
109. Turner D, Levine A, Walters TD, Focht G, Otley A, Navas López V,
Koletzko S, Baldassano R, Mack D, Hyams J, Griffiths AM. Which PCDAI
version best reflects intestinal inflammation in pediatric Crohn’s disease? J
Pediatr Gastroenterol Nutrition 2015; In press
110. Aloi M, Birimberg-Schwartz L, Buderus S, Hojsak I, Fell JM, Bronsky J,
Veereman-Wauters G, Koletzko S, Shaoul R, Miele E, Turner D, Russell
RK. Treatment options and outcomes of pediatric IBDU compared to other
IBD subtypes: a retrospective multicentre study from the ESPGHAN Porto
IBD group. Inflamm Bowel Dis 2016; In press
111. Graph D, Kharenko O, Waxman J, Frankel T, Turner D, Ledder O. Long-
term clinical outcome of neonates with suspected Hirschsprung's disease but
normal rectal biopsy. Eur J Gastroenterol Hepatol 2016; In press
112. Marcovitch L, Nissan A, Mack D, Otley A, Hussey S, Mclean B, Lewis M,
Croft N, Barakat F, Griffiths AM, Turner D. Item generation and reduction
towards developing a Patient Reported Outcome for Pediatric Ulcerative
Colitis (TUMMY-UC). Pediatr Gastroenterol Nutrition 2015; In press
113. Russell RK, Hansen R, Turner D. New treatments for Ulcerative Colitis:
Do we have paediatric data? Exp Rev Clin Epidemiol 2016; In press
Published abstracts (Selected)
1. Turner D, Bernard R, Schlesinger Y, Hammerman C, Schimmel MS. Low levels of
procalcitonin during episodes of necrotizing enterocolitis. Gastroenterology 2005;128
(Supp 2):A133.
2. Turner D, Walsh CM, Steinhart
AH, Griffiths
AM. Response to corticosteroids in
severe ulcerative colitis: a systematic review and a meta-regression. J Ped
Gastroenterol Nutr 2006;43(4):E47.
3. Turner D, Otley AR, de Bruijne J, Mack D, Uusoue K, Zachos M, Mamula P,
Hyams J, Griffiths AM. Development of a Pediatric Ulcerative Colitis Activity Index
(PUCAI). J Ped Gastroenterol Nutr 2006;43(4):E51.
4. Turner D, Steinhart AH, Zlotkin S, Griffiths AM. Meta-analysis of Omega-3 (Fish
Oil) treatment for maintaining remission in IBD. J Ped Gastroenterol Nutr 2006;43
(Suppl 2):S52.
5. Sherlock M, Benchimol EI, Turner D, Walters T, Zachos M, Griffiths AM.
Discontinuation of immunomodulator therapy in infliximab-treated children with
Crohn disease; one year outcome evaluating influences on disease activity and
infliximab antibody formation: Inflam Bowel Dis 2007; 14 (Suppl 1): S26.
6. Turner D, Walsh CM, Chow C, Walters TD, McLernon RA, Griffiths AM.
Intravenous corticosteroid therapy for severe pediatric ulcerative colitis: predictors of
response and outcome. Gastroenterology 2007;132 (Suppl 2):A514.
7. Gana JC, Turner D, Roberts EA, Ng VL, Ling SC. Non-invasive diagnosis of
esophageal varices in children. Gastroenterology 2007;132(Suppl 1):A-824.
8. Turner D, Otley AR, Mack DR, Uusoue K, Walters T, Zachos M, Steinhart AH,
Mamula P, Hyams J, Griffiths AM. The development of a valid, reliable and
11
responsive pediatric ulcerative colitis activity index (PUCAI): a prospective
multicenter study. Gastroenterology 2007;132 (Supp 2):A132.
9. Benchimol EI, Turner D, Mann EH, Thomas KE, Gomes T, McLernon RA, Griffiths
AM. Toxic megacolon in children with inflammatory bowel disease: clinical and
radiologic characteristics. J Ped Gastroenterol Nutr 2007;45 (Suppl 7):E82.
10. Turner D, Walsh CM, Chow C, Walters TD, McLernon RA, Griffiths AM. Severe
pediatric ulcerative colitis: a cohort study of incidence, outcome and predictors of
response. J Ped Gastroenterol Nutr 2007;45 (Suppl 7):E73.
11. Sherlock M, Benchimol EI, Turner D, Walters T, Zachos M, Griffiths AM. One year
outcome following discontinuation of concomitant immunomodulator therapy in
infliximab-treated children with Crohn disease. J Ped Gastroenterol Nutr 2007;45
(Suppl 7):E77.
12. Sivagnanam M, Mueller JL, Lee H, Chen Z, Nelson SF, Turner D, Nagn BY, Zlotkin
SH, Pencharz PB, Libiger O, Schork NJ, Lavine JE, Taylor S, Newbury RO,
Kolodner RD, Hoffman HM. Identification of EpCAM as the Gene for Congenital
Tufting Enteropathy. Gastroenterology 2008;135 (2): 429-437.
13. Turner D, Seow CH, Silverberg MS, Greenberg GR, Griffiths AM, Steinhart AH.
Which Non-Invasive Disease Activity Index Should Be Used in Ulcerative Colitis? A
Systematic Head-to-Head Psychometric Comparison. Gastroenterology 2009;136 (5
Suppl 1):A-161 (Abst 1050).
14. Kabakchiev B*, Turner D* (equal contribution), Hyams JS, Mack DR, LeLeiko NS,
Crandall W, Markowitz J, Otley AR, Xu W, Hu P, Griffiths AM, Silverberg MS.
Gene Expression Profiles Associated with Lack of Response to Intravenous
Corticosteroids in Children with Severe Ulcerative Colitis. Gastroenterology
2009;136 (5 Suppl 1):A-172 (Abst 1107).
15. Turner D, Mack DR, Uusoue K, Hyams JS, Leleiko N, Leach S, Walters TD, Day
AS, Crandall W, Markowitz J, Silverberg MS, Otley AR, Mamula P, Griffiths AM.
Prospective multicenter study of outcomes and predictors of response in severe
pediatric ulcerative colitis. Gastroenterology 2009;136 (5 Suppl 1):A-571 (Abst
T1745).
16. Gana JC, Turner D, Avitzur Y, Ling SC. Prediction of Esophageal Variceal Bleeding
in Children. Gastroenterology 2009;136 (5 Suppl 1):A-825 (Abst S1832).
17. Turner D, Wine E, Kolho K, Mack D, Hyams J, Silverberg MS, Otley AR,
Markowitz J, Crandall W, Leleiko N, Leach, Griffiths AM. Determinants of
corticosteroid-resistance in severe pediatric ulcerative colitis. Inflamm Bowel Dis
2009; 15 (12 Suppl):S16 (Abstr P-38).
18. Turner D, Mack D, Wine E, Hyams JS, Otley AR, Markowitz J, Crandall W,
Mamula P, Leleiko N, Griffiths AM. Infliximab in steroid-refractory pediatric UC:
predictors of response in a prospective multicenter study. JCC 2010; 4 (1):S63 (Abst
P125).
19. Turner D, Mack DR, Wine E, Hyams JS, Otley AR, Markowitz J, Crandall W,
Mamula P, LeLeiko NS, Griffiths AM. A prospective multicenter study: outcomes
and predictors of response to infliximab given as a rescue therapy in severe pediatric
ulcerative colitis. Gastroenterology 2010; 138 (5), Suppl 1: S-29 (Abst 149).
20. Sylvester FA*, Turner D* (equal contribution), Draghi A, Uuosoe K, MacLernon
RA, Griffiths AM. Fecal Osteoprotegerin predicts the need for second line therapy in
12
hospitalized children with ulcerative colitis. Gastroenterology 2010; 138 (5), Suppl 1:
S-358 (abst M1226).
21. Durbin M, Wine E, Turner D, Griffiths AM, Kenche H, Stolfi A, Michail S. The gut
microbiome in children with severe ulcerative colitis. Gastroenterology 2010; 138 (5),
Suppl 1: S-28 (abst 148).
22. Levine A, Griffiths AM, Markowitz J, Wilson DC, Turner D, Russell RK, Fell J,
Ruemmele FM, Walters TD, Sherlock M, Dubinsky M, Hyams JS. Pediatric
modification of the Montreal classification for inflammatory bowel disease: The Paris
classification. J Crohn Colitis 2011; 5(1): S5(abst 6).
23. Turner D, Griffiths AM, Walters TD, Seah T, Markowitz J, Pfefferkorn M, Keljo D,
Waxman J, Otley A, Leleiko NS, Mack D, Hyams J, Levine A. Mathematical
weighting of the pediatric Crohn's disease activity index (PCDAI) and comparison
with its other short versions. J Ped Gastroenterol Nutr 2011;52(Suppl 1):E17 (abst
PA-G-0029).
24. Weiss B, Egbaria R, Lerner A, Suchar I, Broide E, Turner D, Pinsk V, Bujanover Y.
Inflammatory bowel disease in children under 2 years of age: clinical characteristics
and outcome. J Ped Gastroenterol Nutr 2011;52(Suppl 1):E146 (abst PO-G-0110).
25. De Bie1 C, Levine A, Turner D, Cucchiara S, Sladek M, Murphy S, Escher J, for the
EUROKIDS Porto IBD Working Group of ESPGHAN. Atypical disease phenotypes
in paediatric ulcerative colitis: 5-year analyses of the EUROKIDS registry. J Crohn
Colitis 2012;6(Suppl 1):S43 (abst P083).
26. Shaoul R, Turner D, Sladek M, Veres G, Veerman-Wauters G, Escher J, Paerregaard
A, Amil Dias J, Lionetti P, Levine A. Limitations of fecal calprotectin at diagnosis in
untreated pediatric Crohn’s disease. J Crohn Colitis 2012;6(Suppl 1):S48 (abst P096).
27. Church P, Turner D, Walters T, Greer ML, Amitai M, Griffiths A. A systematic
review of MR enterography signs of inflammation and damage in Crohn’s disease. J
Crohn Colitis 2012;6(Suppl 1):S84 (abst P188).
28. Levine A, Sladek M, Shaoul R, Veres G, Amil Dias J, Escher J, Turner D. Exclusive
enteral nutrition is superior to corticosteroids and mesalamine for achieving remission
with normalization of CRP in new onset pediatric Crohn’s disease. J Crohn Colitis
2012;6(Suppl 1):S111 (abst P255).
29. Kasirer Y, Segel R, Renbaum P, Algur N, Mevorach R, Rachman Y, Turner D.
Biochemical assay to determine thiopurine S-methyltransferase (TPMT) activity
should be used in the Jewish population, rather than genotyping. J Crohn Colitis
2012;6(Suppl 1):S146 (abst P343).
30. Church PC, Greer ML, Walters TD, Hyams J, Moote D, Koletzko S, Coppenrath E,
De Carpi JM, Riaza L, Griffiths AM, Turner D. MRE cannot replace gastroscopy
(EGD) in assessing the upper gastrointestinal tract in pediatric Crohn’s disease (CD):
results from the ImageKids study. J Crohn Colitis 2014; 8/S2: S14 (abst O-16).
31. Focht G, Traub T, Church P, Walters TD, Greer ML, Amitai M, Cytter R, Castro DA,
Otley A, O’Brien M, Mack DR, Davila J, Griffiths AM, Turner D. Damage and
inflammatory activity in pediatric Crohn’s disease (CD) based on radiologist and
gastroenterologist physician global assessment. J Crohn Colitis 2014; 8/S2: S18 (abst
O-46).
32. Amil Dias J, Kolho KL, Sladek M, Turner D, Pfeffer T, Veres G, Shaoul R, Staiano
A, Escher J, Paerregaard A, Martin de Carpi J, Veereman G, Koletzko S, Shevah O,
13
Finnby L, Dias JA, Levine A. Persistence of growth retardation in pediatric Crohn’s
Disease. J Crohn Colitis 2014; 8/S2: S30 (abst P-76).
33. Turner D, Doveh E, Cohen A, Wilson ML, Wilson DC, Grossman AB, Rosh J, Lu
YL, Noble A, Baldassano R, Levine A, Lerner A, Bousvaros A, Griffiths AM. Oral
versus subcutaneous methotrexate (MTX) in pediatric Crohn’s disease (CD): a
multicenter propensity score (PS) study. J Crohn Colitis 2014; 8/S2: S34 (abst O-29).
34. Lev-Tzion R, Ledder O, Renbaum P, Mevorach R, Algur N, Segel R, Karban A,
Koifman E, Efrati E, Muise A, Turner D. RAC1 polymorphisms and thiopurine
efficacy in children with inflammatory bowel disease. J Crohn Colitis 2014; 8/S2:
S36 (abst P-89).
Oral Presentation at scientific meetings (Selected)
1. Leibovitz E, Turner D, Aran G, Raiz S, Yagupsky P, Leiberman A, Dagan R. Acute
otitis media in infants < 2 months of age: etiology, pathogen susceptibility patterns,
clinical presentation and therapeutic approach (Abstract no. 1973). 40th
Interscience
Conference on Antimicrobial Agents and Chemotherapy, Sept 17-20, 2000, Toronto,
Canada.
2. Turner D, Griffiths AM. Predicting response to corticosteroids therapy in children
with severe UC. The 3rd
North-East Pediatric GI conference, Jan 24-27, 2006,
Ottawa, Canada.
3. Turner D, Otley AR, de Bruijne J, Mack D, Uusoue K, Walters T, Zachos M,
Mamula P, Hyams J, Beaton DE, Steinhart AH, Griffiths AM. A prospective
multicenter study: Development and validation of a Pediatric Ulcerative Colitis
Activity Index. The 1st International Symposium on Pediatric IBD, Nov 23-25, 2006,
Rome, Italy.
4. Turner D, Otley AR, de Bruijne J, Mack D, Uusoue K, Walters T, Zachos M,
Mamula P, Hyams J, Beaton DE, Steinhart AH, Griffiths AM. The development of a
valid, reliable and responsive Pediatric Ulcerative Colitis Activity Index (abstract no.
904). Digestive Disease Week, May 20-23, 2007, Washington DC, USA.
**AWARDED THE AGA FELLOWSHIP ABSTRACT PRIZE**
5. Turner D, Walsh CM, Chow C, Benchimol EI, Mann EH, Thomas KE, Walters TD,
McLernon RA, Griffiths AM. Severe pediatric ulcerative colitis: a cohort study of
incidence, outcome and predictors of response. ISPGHAN annual meeting, Nov 14-
17, 2007, Kfar Blum, Israel.
6. Turner D, Grossman AB, Rosh, J, Kugathasan S, Gilman AR, Baldassano R,
Griffiths AM. Methotrexate following unsuccessful thiopurine therapy in pediatric
Crohn’s disease. ISPGHAN annual meeting, Nov 14-17, 2007, Kfar Blum, Israel.
7. Turner D, Mack D, Uusoue K, Hyams J, Leleiko N, Leach ST, Walters TD, Day AS,
Crandall W, Markowitz J, Silverberg M, Otley AR, Mamula P, Griffiths AM. Severe
pediatric ulcerative colitis: a prospective multicenter study of outcomes and
predictors of response. NASPGHAN annual meeting, Nov 10-15, 2008, San Diego,
USA
8. Kabakchiev B*, Turner D* (equal contribution), Hyams JS, Mack DR, LeLeiko
NS, Crandall W, Markowitz J, Otley AR, Xu W, Hu P, Griffiths AM, Silverberg MS.
Gene expression profiles associated with lack of response to intravenous
14
corticosteroids in children with severe ulcerative colitis. Digestive Disease Week,
May 31-June 3, 2009, Chicago, USA (Abst 1107).
9. Turner D, Seow CH, Silverberg MS, Greenberg GR, Griffiths AM, Steinhart AH.
Which non-invasive disease activity index should be used in ulcerative colitis? A
systematic head-to-head psychometric comparison. Digestive Disease Week, May 31-
June 3, 2009, Chicago, USA (Abst 1050).
10. Durbin M, Wine E, Turner D, Griffiths AM, Kenche H, Stolfi A, Michail S. The gut
microbiome in children with severe ulcerative colitis. Digestive Disease Week, May
1-5, 2010, New Orleans, USA (Abst 148).
11. Turner D, Mack DR, Wine E, Hyams JS, Otley AR, Markowitz J, Crandall W,
Mamula P, LeLeiko NS, Griffiths AM. A prospective multicenter study: outcomes
and predictors of response to infliximab given as a rescue therapy in severe pediatric
ulcerative colitis. Digestive Disease Week, May 1-5, 2010, New Orleans, USA (Abst
149).
12. Turner D, Leach ST, Mack D, Uusoue K, McLernon R, Hyams J, Leleiko N, Walters
TD, Crandall W, Markowitz J, Otley AR, Griffiths AM, Day AS. Fecal calprotectin,
lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a
prospective multicentre comparison of predicting outcomes and monitoring response.
ISPGHAN annual meeting, Oct 14-15, 2010, Maalot, Israel.
13. Turner D, Travis SPL, Griffiths AM, Ruemmele FM, Levine A, Benchimol EI,
Dubinsky M, George A, Baldassano RN, Lamger JC, Shamberger R, Hyams, JS,
Cucchiara S, Bousvaros A, Escher JC, Markowitz J, Wilson DC, van Assche G,
Russelll RK. Consensus guidelines for managing acute severe colitis in children: a
joint statement from ECCO, ESPGHAN, and the Pediatric IBD Porto group.
ISPGHAN annual meeting, Oct 14-15, 2010, Maalot, Israel.
14. Levine A, Griffiths AM, Markowitz J, Wilson DC, Turner D, Russell RK, Fell J,
Ruemmele FM, Walters TD, Sherlock M, Dubinsky M, Hyams JS. Pediatric
modification of the Montreal classification for inflammatory bowel disease: The Paris
classification. ECCO annual meeting, Feb 24-26, 2011, Dublin, Ireland.
15. Turner D, Griffiths AM, Walters TD, Seah T, Markowitz J, Pfefferkorn M, Keljo D,
Waxman J, Otley A, Leleiko NS, Mack D, Hyams J, Levine A. Mathematical
weighting of the pediatric Crohn's disease activity index (PCDAI) and comparison
with its other short versions. ESPGHAN annual meeting, May 26, 2011, Sorento,
Italy
16. Kasirer Y, Segel R, Mevorach R, Soiferman D, Beeri R, Renbaum P, Algur N,
Turner D. Biochemical assay to determine TPMT activity should be used in Jews
rather than genotyping. Israel Gastroenterological Association Annual Meeting, Jan
27th
, 2012, Eilat, Israel **AWARDED THE ASSOCIATION RESEARCH
PRIZE** 17. Levine A, Sladek MK, Shaoul R, Veres G, Amil-Dias J, Escher J, Turner D. The use
of EEN is superior to corticosteroids and mesalamine for achieving remission with
normalization of CRP in new onset pediatric Crohn's disease. Israel
Gastroenterological Association Annual Meeting, Jan 27th
, 2012, Eilat, Israel
18. Levine A, Turner D, Shaoul R. Calprotectin levels at diagnosis in untreated Pediatric
Crohn's disease. Israeli Clinical Paediatric Society Annual Meeting, Feb 1st, 2012, Tel
Aviv
15
19. Martinelli M, Miele E, Cucchiare S, de Carpi JM, Levine A, Mocic A, Paerregard A,
Turner D, Veres G, Staiano A. Clostridium difficile and IBD data from a prospective
comperative multicenter European pediatric study. ESPGHAN annual meeting, Apr
28, 2012, Stockholm
20. Turner D, Griffiths AM, Veereman G, Johnson J, Damaraju L, Blank M, Hyams J.
Endoscopic and clinical predictors of 1-year outcome in children with UC treated
with infliximab: Results from the T72 trial. UEGW, Oct 15th
, 2013, Berlin (OP015)
21. Church P, Greer ML, Griffiths AM, Amitai M, Walters TD, Focht G, Turner D.
Development of MRE-based multi-item measures of inflammation and intestinal
damage in pediatric Crohn’s disease: the ImageKids study. UEGW, Oct 15th
, 2013,
Berlin (OP168)
22. Lev-Tzion, R, Rachman, Y, Ledder, O, Greenberg, Y, Turner, D. Rapid infliximab
Infusion in children: a single center experience. ISPGHAN annual meeting. Jan 10th
2014, Mitzpe Ramon
23. Pfeffer Gik, T, Levine, A, Turner, D, Dias, AJ, Veres, G, Shaoul R, Staiano A,
Escher JC, Kolho KL, Paerregaard A, De Carpi MJ, Veereman WG, Koletzko S,
Shevah O, Finnby L, Sladek M. Use of Normal CRP Remission as an Outcome
Parameter in Pediatric Crohn's Disease : Evaluation of the Porto IBD Group "Growth
Relapse and Outcomes With Therapy" (GROWTH CD) Cohort Study. ISPGHAN
annual meeting. Jan 10th
2014, Mitzpe Ramon
24. Schechter A, Griffiths C, Gana CJ, Shaoul R, Shamir R, Shteyer E, Bdolah- Abram,
T, Turner D. Early endoscopic, laboratory and clinical predictors of poor disease
course in pediatric UC. ISPGHAN annual meeting. Jan 10th
2014, Mitzpe Ramon
25. Turner D, Griffiths C, Gana CJ, Shaoul R, Shamir R, Shteyer E, Bdolah- Abram, T,
Schechter A. Early endoscopic, laboratory and clinical predictors of poor disease
course in pediatric UC. ECCO annual meeting. Feb 20th
2014, Copenhagen, Denmark
26. Church PC, Greer ML, Walters TD, Hyams J, Moote D, Koletzko S, Coppenrath E,
De Carpi JM, Riaza L, Griffiths AM, Turner D. MRE cannot replace gastroscopy
(EGD) in assessing the upper gastrointestinal tract in pediatric Crohn’s disease (CD):
results from the ImageKids study. PIBD meeting, Sept 11th
, Rotterdam, Holland.
27. Turner D, Doveh E, Cohen A, Wilson ML, Wilson DC, Grossman AB, Rosh J, Lu
YL, Noble A, Baldassano R, Levine A, Lerner A, Bousvaros A, Griffiths AM. Oral
versus subcutaneous methotrexate (MTX) in pediatric Crohn’s disease (CD): a
multicenter propensity score (PS) study. PIBD meeting, Sept 11th
, Rotterdam,
Holland.
28. Turner D, Doveh E, Cohen A, Wilson ML, Wilson DC, Grossman AB, Rosh J, Lu
YL, Noble A, Baldassano R, Levine A, Lerner A, Bousvaros A, Griffiths AM. Oral
versus subcutaneous methotrexate (MTX) in pediatric Crohn’s disease (CD): a
multicenter propensity score (PS) study. Israel Gastroenterology Association annual
meeting, Sept 23th
2014, Tel Aviv, Israel.
29. Choshen S, Finnamore H, Auth M, Bdolah T, Shteyer E, Mack D, Hyams J, Leleiko
N, Griffiths AM, Turner D. IV corticosteroid dosing in pediatric acute severe
ulcerative colitis: a multicenter propensity score study. UEGW annual meeting, Oct
21st 2014, Vienna, Austria (Abst OP014).
30. Lev Tzion R, Ledder O, Renbaum P, Mevorach R, Algur N, Segal R, Karban A,
Koifman E, Efrati E, Muise A, Turner D. RAC1 polymorphisms and thiopurines
16
efficacy in children with IBD. UEGW annual meeting, Oct 21st 2014, Vienna, Austria
(Abst OP011).
31. Turner D, Doveh E, Cohen A, Wilson ML, Wilson DC, Grossman AB, Rosh J, Lu
YL, Noble A, Baldassano R, Levine A, Lerner A, Bousvaros A, Griffiths AM. Oral
versus subcutaneous methotrexate in pediatric Crohn’s disease: a multicenter
propensity score study. UEGW annual meeting, Oct 23st 2014, Vienna, Austria (Abst
OP301).
32. Shachar Y, Avitzour M, Chowers Y, Balicer R, Lederman N, Matz E, Rosenblum J,
Eliakim R, Ben-Horin S, Odes S, Pfeffer J, Levy Z, Israeli E, Dotan I, Turner D.
IBD in Israel: High prevalence suggested by health maintenance organizations
administrative databases. ECCO annual meeting, Feb 18th
2015, Barcelona (Abst
DOP015).
33. Turner D, Cameron F, Kolho KL, Kardowsha-Bochenek K, Afzal NA, Paul S,
Romano C, Lionetti P, Hauer AC, MartinezVinson C, Veres G, Birimberg-Schwartz
L. pANCA and ASCA in > 400 children with IBD-U, Crohn’s Colitis and UC – a
longitudinal report from the Porto paediatric IBD group of ESPGHAN. ECCO annual
meeting, Feb 18th
2015, Barcelona (Abst DOP045).
34. Choshen S, Finnamore H, Auth M, Bdolah T, Shteyer E, Mack D, Hyams J, Leleiko
N, Griffiths AM, Turner D. IV corticosteroid dosing in pediatric acute severe
ulcerative colitis: a multicenter propensity score study. ESPGHAN annual meeting,
May 7st 2015, Amsterdam, Holland (Abst SP-G-101).
35. Heshin-Bekenstein M, Turner D, Shamir R, Bar-Meir M, Dagan R, Zevit N,
Silbermintz A. HBs Vaccine versus Pre-S Vaccine Immunization in Children with
Coeliac Disease Previously Vaccinated Against HBV - a Randomized Controlled
Trial. ESPGHAN annual meeting, May 7st 2015, Amsterdam, Holland (Abst PA-H-
0024).
36. Aloi M, Birimberg-Schwartz L, Hojsak I, Buderus S, Paerregaard A, Bronsky J, Fell
J, Koletzko S, Veereman G, Shaoul R, Miele E, Turner D, Richard Russell.
Outcomes of a large cohort of children with IBD-U compared to other IBD subtypes
and treatment options- a longitudinal report from the Porto paediatric IBD group of
ESPGHAN. ESPGHAN annual meeting, May 7st 2015, Amsterdam, Holland (Abst
SP-G-0102).
37. Choshen S, Griffiths AM, Finnamore H, Auth MKH, Shteyer E, Mack D, Hyams J,
Turner D. The availability of calcineurin inhibitors and infliximab in acute severe
colitis have reduced colectomy rates in 283 children admitted during 1990-2012.
UEGW, Oct 27th
2015, Barcelona, Spain (Abst OP231)
38. Turner D. Demographic characteristics of validated inflammatory bowel disease
patients insured in one Israeli HMO. Israel Gastroenterology Association Annual
Meeting, Feb 5th
, 2016, Tel Aviv, Israel
39. Birimberg Schwartz L, Zucker D, Akriv A, Salvatore C, Cameron F, Lazowska I,
Yianni L, Siba P, Kolacek S, Romano C, Buderus S, Pærregaard A, Escher JC,
Turner D. Development and validation of diagnostic criteria for IBD-Unclassified
(IBDU) in children: A multicenter longitudinal study from the Paediatric IBD Porto
group of ESPGHAN. ECCO annual meeting, March 18th
, 2016, Amsterdam
40. Levine A, Kierkuś J, Kori M, Sladek M, Sigall Boneh R, Escher J, Wine E,
Yerushalmi B, Amil Dias J, Shaul R, Akriv A, Zucker D, Turner D. Azithromycin
17
based therapy for induction of remission in mild to moderate active paediatric Crohns
Disease: The multicentre azithromycin for Crohn’s Disease AZCRO trial. ECCO
annual meeting, March 18th
, 2016, Amsterdam (Abst DOP055)
41. Adedokun OJ, Chan D, Padgett L, Xu Y, Hyams J, Turner D, Xu Z, Davis H, Strauss
R. Pharmacokinetics and exposure-response relationships of golimumab in paediatric
patients with moderate to severe Ulcerative Colitis: Results from a multicentre open
label study. ECCO annual meeting, March 18th
, 2016, Amsterdam (Abst DOP056)
Posters presented at scientific meetings (selected)
1. Turner D, Hammerman C, Bernard R, Schlesinger Y, Schimmel MS. Procalcitonin
(PCT): A marker of nosocomial infections in preterm infants? (Abstract no 440A).
Pediatric Academic Societies’ Annual Meeting, May 14-17, 2005, Washington, USA.
2. Turner D, Bernard R, Schlesinger Y, Hammerman C, Schimmel MS. Low levels of
procalcitonin during episodes of necrotizing enterocolitis (Abstract no 41673).
Digestive Disease Week, May 14-19, 2005, Chicago, USA.
3. Turner D, Hammerman C, Bernard R, Schlesinger Y, Schimmel MS. Necrotizing
enterocolitis and procalcitonin: a prospective study (Abstract no 195). 13th
World
Congress of Gastroenterology-GRIT, Sept 7-10, 2005, Montreal, Canada.
4. Turner D, Martin S, Ngan BY, Grant D, Sherman MP. Bowel anastomotic ulceration
following small bowel transplantation (Abstract no 244). NASPGHAN 18th
Annual
Meeting, Oct 20-22, 2005, Salt Lake City, USA.
5. Turner D, Grant D, Martin S, Ngan BY, Sherman MP. Rectal bleeding after bowel
transplantation? Anastomotic ulceration may be the answer! (Abstract no 12).
Canadian Digestive Disease Week (CDDW)-GRIT, Feb 21-27, 2006, Banff, Canada.
**AWARDED BEST POSTER PRIZE**
6. Turner D, Otley AR, de Bruijne J, Mack D, Uusoue K, Walters T, Zachos M,
Mamula P, Hyams J, Beaton DE, Steinhart AH, Griffiths AM. Development of a
Pediatric Ulcerative Colitis Activity Index (PUCAI) (Abstract no 107). NASPGHAN
19th
Annual Meeting, Oct 19-22, 2006, Orlando, FL, USA.
7. Turner D, Walsh C, Steinhart
AH, Griffiths
AM. Response to corticosteroids in
severe ulcerative colitis: a systematic review and a meta-regression (Abstract no 118).
NASPGHAN 19th
Annual Meeting, Oct 19-22, 2006, Orlando, FL, USA.
8. Turner D, Shah P, Zlotkin S, Steinhart AH, Griffiths
AM. Meta-analysis of omega-3
(fish oil) treatment for maintaining remission in IBD. The 1st International
Symposium on Pediatric IBD, Nov 23-25, 2006, Rome, Italy.
9. Turner D, Otley AR, de Bruijne J, Mack DE, Uusoue K, Walters T, Zachos M,
Mamula P, Hyams J, Beaton D, Steinhart AH, Griffiths AM. Development and
evaluation of a pediatric UC activity index (PUCAI) - a prospective multicenter study
(Abstract no 113). Canadian Digestive Disease Week (CDDW), Feb 15-20, 2007,
Banff, Canada.
10. Gana JC, Turner D, Roberts EA, Ng VL, Ling SC. Non-invasive diagnosis of
esophageal varices in children (Abstract no T1648). Digestive Disease Week, May
20-23, 2007, Washington DC, USA. **POSTER OF DISTINCTION**
18
11. Turner D, Walsh CM, Chow C, Benchimol EI, Walters TD, McLernon RA, Griffiths
AM. Outcomes of intravenous corticosteroid therapy for pediatric ulcerative colitis: a
pediatric index can predict response (Abstract no T1315). Digestive Disease Week,
May 20-23, 2007, Washington DC, USA. 12. Benchimol EI, Turner D, Mann EH, Thomas KE, Gomes T, McLernon RA, Griffiths
AM. Toxic megacolon in children with inflammatory bowel disease: clinical and
radiologic characteristics (Abstarct no 213). NASPGHAN 20th
Annual meeting, Oct
25-27, 2007, Salt Lake City, UT, USA.
13. Turner D, Walsh CM, Chow C, Benchimol EI, Walters TD, McLernon RA, Griffiths
AM. Severe pediatric ulcerative colitis: a cohort study of incidence, outcome and
predictors of response (Abstarct no 190). NASPGHAN 20th
Annual meeting, Oct 25-
27, 2007, Salt Lake City, UT, USA.
14. Sherlock M, Benchimol EI, Turner D, Walters T, Zachos M, Griffiths AM. One year
outcome following discontinuation of concomitant immunomodulator therapy in
infliximab-treated children with Crohn disease. (Abstarct no 201). NASPGHAN 20th
Annual meeting, Oct 25-27, 2007, Salt Lake City, UT, USA.
15. Benchimol EI, Turner D, Mann E, McLernon RA, Griffiths AM. Toxic megacolon
in children: clinical and radiologic characteristics. Canadian Digestive Diseases Week
(CDDW), Feb 29–Mar 3, 2008, Montreal, Canada.
16. Turner D, Mack D, Uusoue K, Hyams J, Leleiko N, Leach ST, Walters TD, Day AS,
Crandall W, Markowitz J, Silverberg M, Otley AR, Kugathasan S, Mamula P,
Griffiths AM. Severe pediatric ulcerative colitis: a prospective multicenter cohort
study (interim analysis of the OSCI study). World Congress of Gastroenterology
Hepatology and Nutrition, Aug 17-20, 2008, Brazil.**POSTER OF
DISTINCTION** 17. Gana JC, Turner D, Roberts EA, Ng VL, Ling SC. Non-invasive diagnosis of
esophageal varices in children. Canadian Digestive Disease Week (CDDW), and
Annual Canadian Association for the Study of the Liver (CASL), Feb 29-Mar 3,
2008, Montreal, Canada.
18. Turner D, Leach ST, Mack D, Uusoue K, Hyams J, Leleiko N, Walters TD, Crandall
W, Markowitz J, Silverberg M, Otley AR, Kugathasan S, Mamula P, Griffiths AM,
Day AS. Fecal calprotectin, lactoferrin and S100A12 do not predict outcome in
severe pediatric ulcerative colitis. World Congress of Gastroenterology Hepatology
and Nutrition, Aug 17-20, 2008, Brazil.
19. Turner D, Benchimol EI, Dunn H, Griffiths AM, Frost, K, Scaini V, Avolio J, Ling
SC. Pico-Salax versus Poly-Ethylene Glycol for bowel cleanout before colonoscopy
in children-a randomized controlled trial. World Congress of Gastroenterology
Hepatology and Nutrition, Aug 17-20, 2008, Brazil.
20. Turner D, Mack D, Uusoue K, Hyams J, Leleiko N, Leach ST, Walters TD, Day AS,
Crandall W, Markowitz J, Silverberg M, Otley AR, Kugathasan S, Mamula P,
Griffiths AM. A prospective multicenter study of outcomes and predictors of
response in severe pediatric ulcerative colitis. Falk Symposium: IBD in Different
Ages, Mar 27-28, 2009; Madrid, Spain. **AWARDED BEST RESEARCH
PRIZE**
19
21. Gana JC, Turner D, Avitzur Y, Ling SC. Prediction of esophageal variceal bleeding
in children. Digestive Disease Week, May 31-June 3, 2009, Chicago, USA (Abst
S1832).
22. Turner D, Mack DR, Uusoue K, Hyams JS, Leleiko N, Leach S, Walters TD, Day
AS, Crandall W, Markowitz J, Silverberg MS, Otley AR, Mamula P, Griffiths AM.
Prospective multicenter study of outcomes and predictors of response in severe
pediatric ulcerative colitis. Digestive Disease Week, May 31-June 3, 2009, Chicago,
USA (Abst T1745).**POSTER OF DISTINCTION**
23. Turner D, Wine E, Kolho K, Mack D, Hyams J, Silverberg MS, Otley AR,
Markowitz J, Crandall W, Leleiko N, Leach, Griffiths AM. Determinants of
corticosteroid-resistance in severe pediatric ulcerative colitis. Advances in IBD
(CCFA), Dec 3-5, 2009, Hollywood, Florida, USA (Abstr P-38).
24. Turner D, Mack D, Wine E, Hyams JS, Otley AR, Markowitz J, Crandall W,
Mamula P, Leleiko N, Griffiths AM. Infliximab in steroid-refractory pediatric UC:
predictors of response in a prospective multicenter study. ECCO 5th
congress, Feb 24-
27, 2010, Prague (Abst P125). **POSTER OF DISTINCTION**
25. Sylvester FA*, Turner D* (equal contribution), Draghi A, Uuosoe K, MacLernon
RA, Griffiths AM. Fecal Osteoprotegerin predicts the need for second line therapy in
hospitalized children with ulcerative colitis. Digestive Disease Week, May 1-5, 2010,
New Orleans, USA (Abst M1226).
26. Weiss B, Egbaria R, Lerner A, Suchar I, Broide E, Turner D, Pinsk V, Bujanover Y.
Inflammatory bowel disease in children under 2 years of age: clinical characteristics
and outcome. ESPGHAN annual meeting, May 26, 2011, Sorrento, Italy (Abst PO-G-
00110).
27. De Bie1 C, Levine A, Turner D, Cucchiara S, Sladek M, Murphy S, Escher J, for the
EUROKIDS Porto IBD Working Group of ESPGHAN. Atypical disease phenotypes
in paediatric ulcerative colitis: 5-year analyses of the EUROKIDS registry. ECCO
annual meeting, Feb 17, 2012, Barcelona, Spain (abst P083). **POSTER HIGHLY
COMMENDED** 28. Shaoul R, Turner D, Sladek M, Veres G, Veerman-Wauters G, Escher J, Paerregaard
A, Amil Dias J, Lionetti P, Levine A. Limitations of fecal calprotectin at diagnosis in
untreated pediatric Crohn’s disease. ECCO annual meeting, Feb 17, 2012, Barcelona,
Spain (abst P096).
29. Church P, Turner D, Walters T, Greer ML, Amitai M, Griffiths A. A systematic
review of MR enterography signs of inflammation and damage in Crohn’s disease.
ECCO annual meeting, Feb 17, 2012, Barcelona, Spain (abst P188).
30. Levine A, Sladek M, Shaoul R, Veres G, Amil Dias J, Escher J, Turner D. Exclusive
enteral nutrition is superior to corticosteroids and mesalamine for achieving remission
with normalization of CRP in new onset pediatric Crohn’s disease. ECCO annual
meeting, Feb 17, 2012, Barcelona, Spain (abst P255).
31. Kasirer Y, Segel R, Renbaum P, Algur N, Mevorach R, Rachman Y, Turner D.
Biochemical assay to determine thiopurine S-methyltransferase (TPMT) activity
should be used in the Jewish population, rather than genotyping. ECCO annual
meeting, Feb 17, 2012, Barcelona, Spain (abst P343). **POSTER HIGHLY
COMMENDED**
20
32. Sladek MK, Turner D, Shaoul R, Veres G, Dias JA, Escher J, Levine A. The use of
EEN is superior to corticosteroids and mesalamine for achieving remission with
normalization of CRP in new onset pediatric Crohn's disease. ESPGHAN annual
meeting, Apr 28, 2012, Stockholm, Sweden (abst G-048).
33. Kasirer YM, Turner D, Dayan B, Silbermintz. Scalloping is a reliable marker for
celiac disease. ESPGHAN annual meeting, Apr 28, 2012, Stockholm, Sweden (abst
G-092).
34. De Ridder L, Turner D, Koletzko S, Levine A et al. Cancer and mortality in pediatric
patients with IBD. ESPGHAN annual meeting, May 10th
, 2013, London UK (Abstr
G-084)
35. Church P, Greer ML, Griffiths AM, Amitai M, Walters TD, Focht G, Turner D.
Development of MRE-based multi-item measures of inflammation and intestinal
damage in pediatric Crohn’s disease: the ImageKids study. ECCO annual meeting,
Feb 20th, 2014, Copenhagen, Denmark
36. Koslowsky B, Gupta A, Livovski D, Adar T, Turner D, Hartnell F, Pratico C, Travis
S. The Use of the PUCAI in adults with acute severe UC. DDW, May 4th
2014,
Chicago, USA (Abstr Su1112)
37. Turner D, Levine A, Kolho KL, Shaoul R, Lev-Tzion R, Rachman Y, Ledder O.
Oral antibiotic cocktail (MADOV) for treatment of refractory severe colitis. DDW,
May 4th
2014, Chicago, USA (Abstr Su1388)
38. Church P, Greer ML, Griffiths AM, Amitai M, Walters TD, Cytter Kuint R, Focht G,
Turner D. Development of MRE Based Multi Item Measures of Inflammation and
Intestinal Damage in Paediatric Crohn's Disease: The ImageKids Study. DDW, May
4th
2014, Chicago, USA (Abstr Sa1159)
39. Werlin S, Shteyer E, Yaakov Y, Yerushalmi B, Pinsk V, Klar A, Broide E, Konikoff
F, Shaoul R, Yaron A, Shamir R, Santo E, Turner D, Shamaly H, Kori M, Ferec C,
Ruszniewski P,Wilschanski M. Recurrent acute pancreatitis in Israeli children.
ESPGHAN annual meeting, June 12th
, Jerusalem, Israel (Abstr PD-G-0142)
**POSTER OF DISTINCTION** 40. Turner D, Levine A, Shaoul R, Kaija-Leena K, Rachman Y, Lev Tzion R, Ledder O.
Oral antibiotic cocktail (MaDOV) for treatment of refractory severe colitis.
ESPGHAN annual meeting, June 12th
, Jerusalem, Israel (Abstr PO-G-0167)
41. Rachman Y, Ledder O, Greenberg Y, Turner D, Lev Tzion R. Rapid infliximab
infusion in children: a single center experience. ESPGHAN annual meeting, June
12th
, Jerusalem, Israel (PO-G-0167)
42. Focht G, Traub T, Church P, Walters TD, Greer ML, Amitai M, Cytter R, Castro
DA, Otley A, O’Brien M, Mack DR, Davila J, Griffiths AM, Turner D. Damage and
inflammatory activity in pediatric Crohn’s disease (CD) based on radiologist and
gastroenterologist physician global assessment. PIBD meeting, Sept 11th
, Rotterdam,
Holland (abst P-46).
43. Amil Dias J, Kolho KL, Sladek M, Turner D, Pfeffer T, Veres G, Shaoul R,
Staiano A, Escher J, Paerregaard A, Martin de Carpi J, Veereman G,
Koletzko S, Shevah O, Finnby L, Dias JA, Levine A. Persistence of growth
retardation in pediatric Crohn’s Disease. PIBD meeting, Sept 11th
, Rotterdam,
Holland (abst P-76).
21
44. Lev-Tzion R, Ledder O, Renbaum P, Mevorach R, Algur N, Segel R, Karban A,
Koifman E, Efrati E, Muise A, Turner D. RAC1 polymorphisms and thiopurine
efficacy in children with inflammatory bowel disease. PIBD meeting, Sept 11th
,
Rotterdam, Holland (abst P-89).
45. Aloi M, Birimberg-Schwartz L, Hojsak I, Buderus S, Paerregaard A, Bronsky J, Fell
J, Koletzko S, Veereman G, Shaoul R, Miele E, Turner D, Russell R. Outcomes of a
large cohort of children with IBDU compared to other IBD subtypes and treatment
options – a longitudinal report from the Porto paediatric IBD group of ESPGHAN.
ECCO annual meeting, Feb 18th
2015, Barcelona (Abst P202).
46. Lev-Tzion R, Ledder O, Shteyer E, Turner D. Intermittent vancomycin and
gentamicin as exclusive therapy for severe very early onset IBD. ECCO annual
meeting, Feb 18th
2015, Barcelona (Abst P329).
47. Hyams J, Rosh J, Markowitz J, Kierkus J, Dubinsky M, Turner D, Faubion W,
Eichner S, Lazar A, Li Y. Effect of adalimumab on clinical laboratory parameters in
paediatric Crohn’s Disease patients from IMAgINE. ECCO annual meeting, Feb 18th
2015, Barcelona (Abst P391).
48. Turner D, Finnamore H, Auth MK, Shteyer E, Mack D, Hyams J, Leleiko N,
Griffiths AM, Choshen S. Intravenous corticosteroid dosing in paediatric acute severe
Ulcerative Colitis (ASC): A multicentre propensity score study. ECCO annual
meeting, Feb 18th
2015, Barcelona (Abst P531).
49. Turner D, Cameron F, Kolho KL, Kardowsha-Bochenek K, Afzal NA, Paul S,
Romano C, Lionetti P, Hauer AC, MartinezVinson C, Veres G, Birimberg-Schwartz
L. pANCA and ASCA in > 400 children with IBD-U, Crohn’s Colitis and UC – a
longitudinal report from the Porto paediatric IBD group of ESPGHAN. ESPGHAN
annual meeting, May 7st 2015, Amsterdam, Holland (Abst PO-G-0192).
50. Lev Tzion R, Ledder O, Shteyer E, Turner D. Intermittent vancomycin and
gentamicin as exclusive therapy for severe very early onset IBD. ESPGHAN annual
meeting, May 7st 2015, Amsterdam, Holland (Abst PO-G-0211).
51. Hyams J, Rosh J, Markowitz J, Kierkus J, Dubinsky M, Turner D, Faubion W,
Eichner S, Lazar A, Li Y, Thakkar R. Effect of adalimumab on clinical laboratory
parameters in paediatric Crohn’s disease patients from IMAgINE. ESPGHAN annual
meeting, May 7st 2015, Amsterdam, Holland (Abst PO-G-0209).
52. Marcovitch L, Nissan A, Mack D, Otley A, Hussey S, Kappelman M, Mclean B, Croft
N, Barakat F, Griffiths AM, Dan Turner. Item generation and reduction of the
"TUMMY" index, a newly derived patient reported outcome (PRO) for pediatric
ulcerative colitis. UEGW, Oct 27th
2015, Barcelona, Spain (Abst P0999) Awarded
"poster in the spotlight" presentation 53. Navas-López VM, Martín-de-Carpi J, Grant A, Walters TD, Ruemmele F, Mack D,
Sladek M, Shamir R, Shaoul R, Saeed S, Russell RK, Cytter-Kuint R, Griffiths AM,
Turner D, Otley A. Quality of life in paediatric Crohn’s Disease: Data from
Imagekids study. ECCO annual meeting, March 18th
, 2016, Amsterdam (Abst P113)
54. Church P, Hyams J, Ruemmele F, de Ridder L, Turner D, Griffiths A, on behalf of
the International Paediatric IBD Network (PIBDNet). The great continental divide:
Use of anti-TNF therapy in paediatric IBD is significantly different in North America
compared to other parts of the world. ECCO annual meeting, March 18th
, 2016,
Amsterdam (Abst P345)
22
55. Turner D, Veereman G, Hyams J, Griffiths A, Chan D, Adedokun OJ, Damaraju L,
Strauss R. A multicentre open-label study assessing pharmacokinetics, efficacy, and
safety of subcutaneous golimumab in paediatric patients with moderately-severely
active Ulcerative Colitis. ECCO annual meeting, March 18th
, 2016, Amsterdam (Abst
P522)
